1. 174P First-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: Preliminary monotherapy dose escalation data. (December 2022) Authors: Naing, A.; Wang, J.S.; Sharma, M.R.; Sommerhalder, D.; Gandhi, L.; Oh, D-Y.; Jiang, Y.; Michalski, J.; Lee, J.; Zhou, K.; Taylor, N.; Yan, L.; Roda, J.M.; Blum, L.; Ling, L.; Mikaelian, I.; Depaoli, A.M.; Hanes, V.; Kaplan, D.D.; Lieu, H.D. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗